Skip to main content

Clinical trial BOSTON

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Organ Myeloma
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Karyopharm
EudraCT Identifier 2016-003957-14
Inclusion criteria - Histologically confirmed MM with measurable disease per IMWG guidelines - Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens
Last update